Background: The value of hepatic resection (HR) for huge hepatocellular carcinomas (HCC) (≥ 10 cm in diameter) remains controversial. The aim of this study is to evaluate the efficacy of hepatic resection (HR) for patients with huge HCC.
Methods: A total of 739 patients with huge HCC (≥ 10 cm in diameter) (huge HCC group, n = 244) or small HCC (< 10 cm in diameter) (small HCC group, n = 495) who received initial HR were retrospectively analyzed. Overall survival (OS) and disease-free survival (DFS) were obtained using the Kaplan-Meier method and compared by Log-Rank test. Prognostic factors of huge HCC were identified based on Cox regression analyses.
Results: The hospital mortality of these two groups were similar (P = 0.252). The 5-year OS of huge HCC group and small HCC group were 30.3% and 51.9%, respectively (P < 0.001). Uninodular huge HCC had a significant higher 5-year OS (50.6%) than mutinodular huge HCC (26.9%) (P = 0.016). Multivariate analysis revealed that uninodular huge HCC and absence of PVTT independently predicted better OS for huge HCC patients.
Conclusion: HR is a safe and effective approach for the treatment of huge HCC, especially for the uninodular subtype.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723821 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Application of a deep learning algorithm for the diagnosis of HCC.
JHEP Rep
January 2025
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
Article Synopsis
- Hepatocellular carcinoma (HCC) has a high mortality rate, and current diagnostic methods like LI-RADS often lead to indeterminate results, complicating accurate diagnosis.
- Researchers developed four deep learning models using CT scans, finding that the Spatio-Temporal 3D Convolution Network (ST3DCN) performed best, significantly outperforming standard radiological interpretation in identifying HCC.
- The ST3DCN model demonstrated strong diagnostic accuracy in both internal validation (AUCs up to 0.919) and external testing (AUC of 0.901), indicating its potential as an effective tool for HCC diagnosis.
Circ_0001944 Targets the miR-1292-5p/FBLN2 Axis to Facilitate Sorafenib Resistance in Hepatocellular Carcinoma by Impeding Ferroptosis.
Immunotargets Ther
November 2024
Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, People's Republic of China.
Background: Sorafenib, an orally active potent tyrosine kinase inhibitor (TKI), represented a primary treatment in patients with advanced hepatocellular carcinoma (HCC). Unfortunately, sorafenib resistance was regarded as a huge obstacle for HCC treatment.
Methods: RNA-sequencing including circRNA Sequencing (circRNA-Seq) for circular RNAs (circRNAs), miRNA Sequencing (miRNA-Seq) for microRNAs (miRNAs), as well as mRNA Sequencing (mRNA-Seq) for mRNAs in , were performed.
A Contemporary Review of Robotic Resection for Hepatocellular Carcinoma.
Cancers (Basel)
November 2024
Department of Surgery, Division of Transplantation, Sidney Kimmel Medical College, Thomas Jefferson University, 1015 Walnut Street, Curtis Building, Suite 613, Philadelphia, PA 19107, USA.
: Robotic hepatectomy represents an appealing treatment modality for resectable hepatocellular carcinoma (HCC). A contemporary review of robotic hepatectomy compared to laparoscopic/open hepatectomy is necessary. : We performed a literature review to identify studies between 2018-2024 comparing robotic to laparoscopic/open hepatectomy for HCC with measurable outcomes.
View Article and Find Full Text PDFFerroptosis: insight into the treatment of hepatocellular carcinoma.
Cancer Cell Int
November 2024
Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Hepatocellular carcinoma (HCC) is one of the most common malignances in the world, with high morbidity and mortality. Due to the hidden onset of symptoms, there are huge obstacles in early diagnosis, recurrence, metastasis and drug resistance. Although great strides have been made in the treatment of HCC, effective treatment options are still limited and achieving longer survival for patients remains urgent.
View Article and Find Full Text PDFEconomic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives.
Clinicoecon Outcomes Res
October 2024
Department of Drug Sciences, University of Pavia, Pavia, Italy.
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising health issue in Italy, with the study evaluating its economic burden on the National Healthcare Service.
- Utilizing an Excel model, researchers compared healthcare costs and complications associated with MASLD against a similar population without it, revealing significant financial and mortality impacts.
- The study estimates that MASLD could cost the Italian healthcare system over €12 billion annually and result in approximately 13,438 extra deaths, highlighting the need for lifestyle changes and future pharmaceutical interventions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!